OX40 receptor agonist / BioInvent, Cancer Research UK - LARVOL DELTA

FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms. (PubMed, Cell Rep) - "We demonstrate that signaling through the hFcγRIIB ITIM is dispensable for impairing monoclonal antibody (mAb)-mediated depletion of normal and malignant murine target cells through three therapeutically relevant surface receptors (CD20, CD25, and OX40) affecting immunotherapy. We demonstrate that hFcγRIIB competition with activating FcγRs for antibody Fc, rather than ITIM signaling, is sufficient to impair activating FcγR engagement, inhibiting effector function and immunotherapy."

Journal • Immunology • Oncology • CD20 • FCGR2B • IL2RA